I-Mab (IMAB) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

IMAB Stock Forecast

I-Mab stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

IMAB Analyst Ratings

Buy

According to 2 Wall Street analysts, I-Mab's rating consensus is 'Buy'. The analyst rating breakdown for IMAB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 16, 2024	Piper Sandler	Overweight	Overweight	Hold
Mar 18, 2024	Piper Sandler	Overweight	Overweight	Hold
Aug 17, 2022	Needham	Buy	Buy	Hold
Jun 07, 2022	Piper Sandler	Overweight	Overweight	Hold

Row per page

Go to

I-Mab's last stock rating was published by Piper Sandler on Sep 16, 2024. The company gave IMAB a "Overweight" rating, the same as its previous rate.

I-Mab Financial Forecast

I-Mab Revenue Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	$10.71M	$10.71M	-	$49.99M	$549.94M	$239.97M	$957.27M	$957.27M	-	$5.45M	$14.17M
High Forecast	-	-	$10.71M	$10.71M	-	$49.99M	$549.94M	$239.97M	$957.27M	$957.27M	-	$5.45M	$14.17M
Low Forecast	-	-	$10.71M	$10.71M	-	$49.99M	$549.94M	$239.97M	$957.27M	$957.27M	-	$5.45M	$14.17M
# Analysts	-	-	1	1	-	1	1	1	1	1	-	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-

I-Mab's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMAB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

I-Mab EBITDA Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23
# Analysts	-	-	1	1	-	1	1	1	1	1	-	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	$-4.05M	$-4.05M	-	$-18.91M	$-207.97M	$-90.75M	$-362.02M	$-362.02M	-	$-2.06M	$-5.36M
High Forecast	-	-	$-4.05M	$-4.05M	-	$-18.91M	$-207.97M	$-90.75M	$-362.02M	$-362.02M	-	$-2.06M	$-5.36M
Low Forecast	-	-	$-4.05M	$-4.05M	-	$-18.91M	$-207.97M	$-90.75M	$-362.02M	$-362.02M	-	$-2.06M	$-5.36M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict IMAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than I-Mab's previous annual EBITDA (undefined) of $NaN.

I-Mab Net Income Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23
# Analysts	-	-	1	1	-	1	1	1	1	1	-	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-86.70M	$-86.70M	-	-	$-398.75M	$-405.20M	$144.50M	$-384.32M	$714.02M	$714.02M	$-272.33M	$-180.55M	$-481.60M
High Forecast	$-86.70M	$-86.70M	-	-	$-398.75M	$-405.20M	$144.50M	$-384.32M	$714.02M	$714.02M	$-272.33M	$-180.55M	$-481.60M
Low Forecast	$-86.70M	$-86.70M	-	-	$-398.75M	$-405.20M	$144.50M	$-384.32M	$714.02M	$714.02M	$-272.33M	$-180.55M	$-481.60M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-

I-Mab's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

I-Mab SG&A Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23
# Analysts	-	-	1	1	-	1	1	1	1	1	-	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	$66.28M	$96.44M	-	$309.29M	$3.40B	$1.48B	$5.92B	$5.92B	-	$33.72M	$87.65M
High Forecast	-	-	$66.28M	$96.44M	-	$309.29M	$3.40B	$1.48B	$5.92B	$5.92B	-	$33.72M	$87.65M
Low Forecast	-	-	$66.28M	$96.44M	-	$309.29M	$3.40B	$1.48B	$5.92B	$5.92B	-	$33.72M	$87.65M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-

I-Mab's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMAB last annual SG&A of $NaN (undefined).

I-Mab EPS Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23
# Analysts	-	-	1	1	-	1	1	1	1	1	-	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-1.07	$-1.07	-	-	$-4.93	$-5.01	$1.79	$-4.75	$8.82	$8.82	$-3.36	$-2.23	$-5.95
High Forecast	$-1.07	$-1.07	-	-	$-4.93	$-5.01	$1.79	$-4.75	$8.82	$8.82	$-3.36	$-2.23	$-5.95
Low Forecast	$-1.07	$-1.07	-	-	$-4.93	$-5.01	$1.79	$-4.75	$8.82	$8.82	$-3.36	$-2.23	$-5.95
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, I-Mab's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMAB previous annual EPS of $NaN (undefined).

I-Mab Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IMAB	I-Mab	$0.96	$35.00	3545.83%	Buy
STTK	Shattuck Labs	$1.01	$12.00	1088.12%	Hold
LYEL	Lyell Immunopharma	$0.92	$6.67	625.00%	Hold
APLS	Apellis Pharmaceuticals	$27.75	$74.50	168.47%	Buy
CGEM	Cullinan Oncology	$12.22	$31.50	157.77%	Buy
ERAS	Erasca	$2.60	$6.50	150.00%	Buy
FHTX	Foghorn Therapeutics	$7.72	$16.33	111.53%	Buy
DSGN	Design Therapeutics	$5.57	$9.67	73.61%	Buy
IMVT	Immunovant	$26.54	$42.83	61.38%	Buy
ASND	Ascendis Pharma	$122.64	$190.21	55.10%	Buy
AKRO	Akero Therapeutics	$31.20	$46.00	47.44%	Buy
NRIX	Nurix Therapeutics	$22.37	$32.20	43.94%	Buy
BGNE	BeiGene	$194.56	$255.80	31.48%	Buy
KYMR	Kymera Therapeutics	$43.51	$51.50	18.36%	Buy
BPMC	Blueprint Medicines	$96.62	$109.71	13.55%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$56.78	$60.63	6.78%	Buy
KRYS	Krystal Biotech	$182.29	$191.00	4.78%	Buy
GRCL	Gracell Bio	$10.25	$6.00	-41.46%	Buy

IMAB Forecast FAQ

Is I-Mab a good buy?

Yes, according to 2 Wall Street analysts, I-Mab (IMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of IMAB's total ratings.

What are I-Mab's analysts' financial forecasts?

I-Mab's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $962.72M (high $962.72M, low $962.72M), average EBITDA is $-364M (high $-364M, low $-364M), average net income is $261.14M (high $261.14M, low $261.14M), average SG&A $5.96B (high $5.96B, low $5.96B), and average EPS is $3.23 (high $3.23, low $3.23). IMAB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $71.42M (high $71.42M, low $71.42M), average EBITDA is $-27.01M (high $-27.01M, low $-27.01M), average net income is $-804M (high $-804M, low $-804M), average SG&A $472.01M (high $472.01M, low $472.01M), and average EPS is $-9.934 (high $-9.934, low $-9.934).